BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15581057)

  • 1. Tailored chemotherapy for colorectal cancer: a new approach to therapy.
    Iqbal S; Stoehlmacher J; Lenz HJ
    Cancer Invest; 2004; 22(5):762-73. PubMed ID: 15581057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of genetic testing in the management of colorectal cancer.
    Stoehlmacher J; Lenz HJ
    Am J Pharmacogenomics; 2003; 3(2):73-88. PubMed ID: 12749725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients.
    Gnoni A; Russo A; Silvestris N; Maiello E; Vacca A; Marech I; Numico G; Paradiso A; Lorusso V; Azzariti A
    Curr Drug Metab; 2011 Dec; 12(10):918-31. PubMed ID: 21787270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
    Koopman M; Venderbosch S; Nagtegaal ID; van Krieken JH; Punt CJ
    Eur J Cancer; 2009 Jul; 45(11):1935-49. PubMed ID: 19473832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
    Shimamoto Y; Nukatsuka M; Takechi T; Fukushima M
    Int J Mol Med; 2016 Feb; 37(2):319-28. PubMed ID: 26676887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
    Koopman M; Venderbosch S; van Tinteren H; Ligtenberg MJ; Nagtegaal I; Van Krieken JH; Punt CJ
    Eur J Cancer; 2009 Jul; 45(11):1999-2006. PubMed ID: 19457654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes.
    Gustavsson B; Kaiser C; Carlsson G; Wettergren Y; Odin E; Lindskog EB; Niyikiza C; Ma D
    Int J Cancer; 2009 Mar; 124(5):1220-6. PubMed ID: 19051292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
    Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
    J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of excision repair cross-complementation group 1 in colorectal cancer.
    Bohanes P; Labonte MJ; Lenz HJ
    Clin Colorectal Cancer; 2011 Sep; 10(3):157-64. PubMed ID: 21855036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?
    Graziano F; Cascinu S
    Ann Oncol; 2003 Jul; 14(7):1026-38. PubMed ID: 12853343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.
    Uchida K; Hayashi K; Kuramochi H; Takasaki K
    Int J Oncol; 2001 Aug; 19(2):341-6. PubMed ID: 11445849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
    Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ
    Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
    Lassmann S; Hennig M; Rosenberg R; Nährig J; Schreglmann J; Krause F; Poignee-Heger M; Nekarda H; Höfler H; Werner M
    Int J Colorectal Dis; 2006 Apr; 21(3):238-47. PubMed ID: 16132996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients.
    Gajjar KK; Vora HH; Kobawala TP; Trivedi TI; Ghosh NR
    Int J Biol Markers; 2018 May; 33(2):180-188. PubMed ID: 29799355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive and prognostic factors in the neoadjuvant/adjuvant therapy of gastrointestinal tumors: wishful thinking or reality?].
    Vallböhmer D; Lenz HJ
    Zentralbl Chir; 2006 Apr; 131(2):148-56. PubMed ID: 16612782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.
    Bahrami A; Amerizadeh F; Hassanian SM; ShahidSales S; Khazaei M; Maftouh M; Ghayour-Mobarhan M; Ferns GA; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2193-2201. PubMed ID: 28422287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
    Schmoll HJ
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):34-9. PubMed ID: 12422306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
    Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
    Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.